Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium®
Target Selector™ platform demonstrates ability to accurately detect, enumerate, and interrogate circulating tumor cells (CTCs) in a cohort of over 1,500 patients, representing various clinical and treatment stages of breast cancer SAN DIEGO , Dec. 3, 2019 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
Biocept's patented Target Selector™ test for identification of TRK proteins enables physicians to rapidly and cost-effectively identify the potential presence of NTRK fusions used to inform on treatment options SAN DIEGO , Nov. 21, 2019 /PRNewswire/ -- Biocept, Inc.
View HTML
Toggle Summary Biocept Reports Third Quarter 2019 Financial Results
- Revenues reached a record $1.5 million, up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019 - The number of commercial samples received increased 66% over the third quarter of 2018 and 12% over the second quarter of 2019 - Cost of revenue reduced 23% on a per
View HTML
Toggle Summary Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe
Patented Blood Collection Tube and Sample Collection Shipping Kit enable the safe transport at room temperature of patient specimens containing both circulating tumor DNA or RNA (ctDNA or ctRNA) and circulating tumor cells (CTCs) SAN DIEGO , Nov. 7, 2019 /PRNewswire/ --  Biocept, Inc.
View HTML
Toggle Summary Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019
SAN DIEGO , Nov. 6, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
View HTML
Toggle Summary Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting
Data highlight strong analytical and clinical performance of Biocept's proprietary technologies, including circulating tumor DNA (ctDNA) assays, circulating tumor cell (CTC) capture, and molecular testing kits SAN DIEGO , Nov. 4, 2019 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE
Limit of detection of 0.02% or better enables accurate molecular profiling for treatment selection and dynamic monitoring of response to therapy using a simple blood sample     SAN DIEGO , Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
View HTML
Toggle Summary Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform
Expands intellectual property to 37 issued patents globally for highly sensitive methods of detecting cancer biomarkers     SAN DIEGO , Oct. 3, 2019 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
View HTML
Toggle Summary Biocept to Present at Two Investment Conferences in September
SAN DIEGO , Sept. 3, 2019 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that management will present at
View HTML
Toggle Summary High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer
Data highlight the ability of Biocept's patented and proprietary circulating tumor DNA assays to consistently detect actionable biomarkers from the blood of patients diagnosed with lung cancer at a mutant allele frequency as low as 0.01% SAN DIEGO , Aug. 22, 2019 /PRNewswire/ --  Biocept, Inc .
View HTML